Fig. 11

The MAO-B/5-HIAA/GPR35 and MAO-B/ROS pathways are essential for FMD-induced NETs reduction and pain relief. A. Schematic of the experimental timeline to explore the necessity of MAO-B and its downstream products for FMD-induced NETs reduction and pain relief. B. Paw withdrawal threshold of mice (n = 6, group: F_{4, 20} = 152, P < 0.0001; time: F_{4, 20} = 143.7, P < 0.0001; interaction: F_{16, 80} = 16.33, P < 0.0001). C. Paw withdrawal latency of mice (n = 6, group: F_{4, 20} = 193.8, P < 0.0001; time: F_{4, 20} = 331.4, P < 0.0001; interaction: F_{16, 80} = 29.24, P < 0.0001). D. Representative blots and quantification of MAO-B in the spinal cords (n = 5, F_{3, 16} = 35.77, P < 0.0001). E and F. ROS production in the spinal dorsal horns assessed by flow cytometry using DCFH-DA (n = 5, F_{3, 16} = 56.4, P < 0.0001). G. ELISA detection of 5-HIAA in the spinal dorsal horns (n = 5, F_{3, 16} = 72.25, P < 0.0001). H. Double immunofluorescence staining for MAO-B (red) and GFAP (green) in the spinal cords (n = 3, scale bars: 50 or 100 μm). I. Representative blots and quantification of GPR35 in the spinal cords of vehicle, FMD, FMD + selegiline, and FMD + 5-HIAA + PMA groups (n = 5, F_{3, 16} = 23.56, P < 0.0001). J and K. Representative blots and quantification of MPO and citH3 in the spinal cords of vehicle, FMD, FMD + selegiline, and FMD + 5-HIAA + PMA groups (n = 5, MPO: F_{3, 16} = 28.35, P < 0.0001; citH3: F_{3, 16} = 13.39, P = 0.0001). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared with the vehicle group mice. #P < 0.05, compared with the FMD group mice. &P < 0.05, compared with the selegiline group mice